MediWound Ltd. (NASDAQ:MDWD) – Equities researchers at Jefferies Group dropped their Q3 2017 earnings per share (EPS) estimates for shares of MediWound in a research report issued to clients and investors on Thursday. Jefferies Group analyst R. Denhoy now forecasts that the biopharmaceutical company will post earnings per share of ($0.20) for the quarter, down from their prior forecast of ($0.16). Jefferies Group also issued estimates for MediWound’s FY2017 earnings at ($0.81) EPS, FY2018 earnings at ($0.85) EPS and FY2019 earnings at ($0.84) EPS.

Other equities research analysts have also issued reports about the stock. SunTrust Banks, Inc. reiterated a “buy” rating on shares of MediWound in a research report on Monday, June 26th. Aegis reiterated a “buy” rating and issued a $11.00 price objective on shares of MediWound in a research report on Thursday, May 25th. Oppenheimer Holdings, Inc. set a $10.00 price objective on shares of MediWound and gave the stock a “buy” rating in a research report on Monday, May 8th. Finally, Zacks Investment Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $10.19.

TRADEMARK VIOLATION WARNING: “Q3 2017 Earnings Estimate for MediWound Ltd. (NASDAQ:MDWD) Issued By Jefferies Group” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/08/q3-2017-earnings-estimate-for-mediwound-ltd-nasdaqmdwd-issued-by-jefferies-group.html.

Shares of MediWound (MDWD) opened at 6.85 on Monday. The firm’s market capitalization is $150.22 million. The stock has a 50 day moving average of $6.96 and a 200-day moving average of $6.41. MediWound has a 12 month low of $4.25 and a 12 month high of $8.58.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.01. The business had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. MediWound’s quarterly revenue was up 93.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.34) earnings per share.

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its stake in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 7,900 shares in the last quarter. Wells Fargo & Company MN raised its stake in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. Institutional investors and hedge funds own 27.32% of the company’s stock.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.